NEW YORK (GenomeWeb) – Foundation Medicine is making efforts on several fronts to increase reimbursement for its cancer genomic profiling tests by public and private payors in the US and abroad, including submitting its FoundationOne test for parallel review by the US Food and Drug Administration and the Centers for Medicare and Medicaid Services and opening a laboratory in Germany to take advantage of that country's recently updated reimbursement codes.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.